Results 191 to 200 of about 15,540,926 (301)

Tumor‐Targeted Hyaluronic Acid/Tannic Acid‐Engineered Oxygen Nanogenerators With IR780 Payloads Enable Dual‐Mode Glutathione Depletion and Effective Singlet Oxygen Generation for Melanoma Treatment

open access: yesAdvanced Healthcare Materials, EarlyView.
A hyaluronic acid/tannic acid‐engineered Prussian blue oxygen nanogenerator loaded with IR780 is developed to enhance melanoma phototherapy. By integrating tumor targeting, oxygen self‐supply, and dual‐mode glutathione depletion, the nanoplatform effectively overcomes hypoxia and antioxidant defenses, potentiating synergistic photothermal/photodynamic ...
Chai‐How Hsu   +7 more
wiley   +1 more source

Immunotherapies inducing immunogenic cell death in cancer: insight of the innate immune system. [PDF]

open access: yesFront Immunol, 2023
Calvillo-Rodríguez KM   +4 more
europepmc   +1 more source

Overcoming Photodynamic Therapy Resistance: GSH‐Responsive AIE Photosensitizer‐Hydroxycamptothecin Nanoliposomes for Extrahepatic Cholangiocarcinoma

open access: yesAdvanced Healthcare Materials, EarlyView.
A GSH‐responsive AIE nanoplatform (TSH NPs) with RGD‐mediated tumor targeting co‐delivers a photosensitizer (TPA) and HCPT for extrahepatic cholangiocarcinoma. The system synergistically enhances PDT and chemotherapy by suppressing HIF‐1α/VEGF‐driven hypoxic adaptation, effectively overcoming PDT resistance.
Yong Qu   +19 more
wiley   +1 more source

How is Nanoarchitectonics Shaping Extracellular Vesicle Research?

open access: yesAdvanced Healthcare Materials, EarlyView.
The convergence of nanoarchitectonics and extracellular vesicle biology is reshaping next‐generation nanomedicine by enabling rationally designed nanostructures for enhanced EVs detection, engineering, and therapy. ABSTRACT Extracellular vesicles (EVs) have gained recognition as crucial mediators of cell‐to‐cell communication, holding immense potential
Madushani Dahanayake   +5 more
wiley   +1 more source

Heatstroke-induced acute kidney injury and the innate immune system. [PDF]

open access: yesFront Med (Lausanne), 2023
Goto H, Kinoshita M, Oshima N.
europepmc   +1 more source

Making the Case for Organ‐on‐Chip Platforms in Long‐Acting Therapeutics Development

open access: yesAdvanced Healthcare Materials, EarlyView.
LATs release drug from a tissue‐resident depot over weeks to months, improving adherence, but their development is hampered by preclinical models that cannot reproduce the coupled tissue processes, sustained release, local microenvironment change, interstitial transport, immune and foreign‐body responses, and clearance that govern depot performance in ...
Charlie Gowans   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy